MEDI-547 (anti-EphA2)

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab177913-100μg	100μg	现货
Ab177913-1mg	1mg	现货
Ab177913-5mg	5mg	现货
Ab177913-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: EPHA2

Accession#:P29317 (4) EphA2 (4) Gene ID:1969 (4)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	MEDI-547 (anti-EphA2)
英文别名	EC 2.7.10.1 \| Epithelial cell kinase \| Tyrosine-protein kinase receptor ECK
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	EPHA2
种属反应性	人(Human)
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	26.3 kDa (Light Chain) & 53.2 kDa (Heavy Chain), under reducing conditions; 187.7 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

EPHA2 Tclin 肝素 A 型受体 2(Ephrin type-A receptor 2) (0 活性数据)

点击查看靶蛋白信息： EPHA2

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

EPHA2 Tclin Ephrin type-A receptor 2 (3499 活性数据)

点击查看靶蛋白信息： EPHA2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

EPHA2 Tclin Ephrin receptor (0 活性数据)

点击查看靶蛋白信息： EPHA2

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

ELISA: MEDI-547 (anti-EphA2) (Ab177913)

MEDI-547 (anti-EphA2) (Ab177913) - ELISA
Immobilized Cynomolgus/Rhesus Macaque EphA2-his at 2.0 μg/mL can bind MEDI-547 (anti-EphA2) (Ab177913) with the EC₅₀ of 12.25 ng/mL.

SEC: MEDI-547 (anti-EphA2) (Ab177913)

MEDI-547 (anti-EphA2) (Ab177913) - SEC
The purity of MEDI-547 (anti-EphA2) (Ab177913) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F0404063	分析证书	Ab177913
ZJ24F0404062	分析证书	Ab177913
ZJ24F0404061	分析证书	Ab177913

可替换产品

引用文献

1. Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN, Swanson RV et al.. (2002) Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography.. Structure, 10 (12): (1659-67). [PMID:12467573]
2. Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB et al.. (2010) Architecture of Eph receptor clusters.. Proc Natl Acad Sci USA, 107 (24): (10860-5). [PMID:20505120]
3. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.. J Biol Chem, 282 (33): (24463-70). [PMID:17562705]
4. Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY. (2012) Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.. Bioorg Med Chem Lett, 22 (23): (7232-6). [PMID:23099099]
5. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al.. (2012) Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.. J Med Chem, 55 (3): (1082-105). [PMID:22168626]
6. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568]
7. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE. (2010) The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.. Bioorg Med Chem Lett, 20 (22): (6394-9). [PMID:20932747]
8. Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S et al.. (2013) Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.. J Med Chem, 56 (7): (2936-47). [PMID:23489211]
9. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
10. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A et al.. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.. J Med Chem, 54 (22): (7797-814). [PMID:21888439]
11. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.. J Med Chem, 58 (17): (6875-98). [PMID:26222319]
12. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
13. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428]
14. Wang Z, Zhang Y, Pinkas DM, Fox AE, Luo J, Huang H, Cui S, Xiang Q, Xu T, Xun Q et al.. (2018) Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2.. J Med Chem, 61 (17): (7977-7990). [PMID:30075624]
15. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.. J Med Chem, 61 (24): (11398-11414). [PMID:30480444]
16. Park JE et al.. (2012) Human Cataract Mutations in EPHA2 SAM Domain Alter Receptor Stability and Function.. PLoS One, 7 (5): (e36564). [PMID:22570727]
17. Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT,. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.. Science, [PMID:20223987]
18. Chu JJ, Yang PL.. (2007) c-Src protein kinase inhibitors block assembly and maturation of dengue virus.. Proc Natl Acad Sci U S A, 104 (9): (3520-3525). [PMID:17360676] [10.1073/pnas.0611681104]
19. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT.. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor.. J Biol Chem, 282 (20): (14845-14852). [PMID:17395594] [10.1074/jbc.m606695200]
20. Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B.. (2009) Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.. J Med Chem, 52 (17): (5531-5545). [PMID:19678708] [10.1021/jm9008604]
21. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
22. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
23. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461] [10.1021/jm200975u]
24. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (5): (1864-1869). [PMID:22335897] [10.1016/j.bmcl.2012.01.084]
25. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818] [10.1021/jm300309a]
26. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479] [10.1016/j.bmcl.2012.10.016]
27. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z.. (2013) Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor.. ACS Med Chem Lett, 4 (3): (344-348). [PMID:24167659] [10.1021/ml3004523]
28. Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.. (2013) Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).. Eur J Med Chem, 61 (95-103). [PMID:23047001] [10.1016/j.ejmech.2012.09.021]
29. Lafleur K, Dong J, Huang D, Caflisch A, Nevado C.. (2013) Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.. J Med Chem, 56 (1): (84-96). [PMID:23253074] [10.1021/jm301187e]
30. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083]
31. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576] [10.1021/jm501929n]
32. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.. (2015) Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.. J Med Chem, 58 (9): (3957-3974). [PMID:25835317] [10.1021/acs.jmedchem.5b00270]
33. Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.. (2015) Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.. J Med Chem, 58 (10): (4165-4179). [PMID:25965804] [10.1021/acs.jmedchem.5b00067]
34. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
35. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
36. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
37. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
38. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
39. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ.. (2017) Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.. Eur J Med Chem, 134 (147-158). [PMID:28411455] [10.1016/j.ejmech.2017.03.085]
40. Shi Y, Challa S, Sang P, She F, Li C, Gray GM, Nimmagadda A, Teng P, Odom T, Wang Y, van der Vaart A, Li Q, Cai J.. (2017) One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.. J Med Chem, 60 (22): (9290-9298). [PMID:29111705] [10.1021/acs.jmedchem.7b01280]
41. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.. (2018) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.. J Med Chem, 61 (1): (140-157). [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
42. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
43. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T.. (2018) Identification and biological evaluation of thiazole-based inverse agonists of RORγt.. Bioorg Med Chem Lett, 28 (9): (1446-1455). [PMID:29631962] [10.1016/j.bmcl.2018.03.093]
44. Petty A, Idippily N, Bobba V, Geldenhuys WJ, Zhong B, Su B, Wang B.. (2018) Design and synthesis of small molecule agonists of EphA2 receptor.. Eur J Med Chem, 143 (1261-1276). [PMID:29128116] [10.1016/j.ejmech.2017.10.026]
45. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V.. (2017) Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.. Bioorg Med Chem, 25 (24): (6523-6535). [PMID:29089259] [10.1016/j.bmc.2017.10.032]
46. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020]
47. Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M.. (2018) Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.. J Med Chem, 61 (5): (2052-2061). [PMID:29470068] [10.1021/acs.jmedchem.7b01837]
48. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.. (2018) Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.. Eur J Med Chem, 145 (606-621). [PMID:29348070] [10.1016/j.ejmech.2017.12.041]
49. Lodola A, Giorgio C, Incerti M, Zanotti I, Tognolini M.. (2017) Targeting Eph/ephrin system in cancer therapy.. Eur J Med Chem, 142 (152-162). [PMID:28780190] [10.1016/j.ejmech.2017.07.029]
50. Wang L, Zhang Y, Zhang Q, Zhu G, Zhang Z, Duan C, Lu T, Tang W.. (2019) Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.. Eur J Med Chem, 163 (243-255). [PMID:30529543] [10.1016/j.ejmech.2018.11.033]
51. Tang G, Liu L, Wang X, Pan Z.. (2019) Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).. Eur J Med Chem, 173 (167-183). [PMID:30999237] [10.1016/j.ejmech.2019.03.055]
52. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
53. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (309-329). [PMID:31096153] [10.1016/j.ejmech.2019.04.035]
54. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015]
55. Lindberg, R A RA and Hunter, T T.. (1990) cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases.. Molecular and cellular biology, [PMID:2174105]
56. (1997) Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee.. Cell, (8): [PMID:9267020]
57. Miao, H H, Burnett, E E, Kinch, M M, Simon, E E and Wang, B B.. (2000) Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.. Nature cell biology, [PMID:10655584]
58. Zelinski, D P DP, Zantek, N D ND, Stewart, J C JC, Irizarry, A R AR and Kinch, M S MS.. (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells.. Cancer research, (1): [PMID:11280802]
59. Kikawa, Keith D KD, Vidale, Derika R DR, Van Etten, Robert L RL and Kinch, Michael S MS.. (2002) Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation.. The Journal of biological chemistry, (18): [PMID:12167657]
60. Tanaka, Masamitsu M, Kamata, Reiko R and Sakai, Ryuichi R.. (2005) EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability.. The Journal of biological chemistry, (23): [PMID:16236711]
61. Liu, Dong-Ping DP, Wang, Yan Y, Koeffler, H Phillip HP and Xie, Dong D.. (2007) Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK.. International journal of oncology, [PMID:17332925]
62. Zhang, Guoqi G and 5 more authors.. (2008) EphA2 is an essential mediator of UV radiation-induced apoptosis.. Cancer research, (15): [PMID:18339848]
63. Jin, Pei P and 9 more authors.. (2008) Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.. Arthritis research & therapy, [PMID:18593464]
64. Wykosky, J J and 5 more authors.. (2008) Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.. Oncogene, (11): [PMID:18794797]
65. Shiels, Alan A and 6 more authors.. (2008) The EPHA2 gene is associated with cataracts linked to chromosome 1p.. Molecular vision, [PMID:19005574]
66. Zhang, Tianxiao T and 12 more authors.. (2009) Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract.. Human mutation, [PMID:19306328]
67. Himanen, Juha P JP and 9 more authors.. (2009) Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.. EMBO reports, [PMID:19525919]
68. Annamalai, Balasubramaniam; Liu, Xueguang; Gopal, Udhayakumar and Isaacs, Jennifer S.. (2009) Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.. Molecular cancer research : MCR, [PMID:19567782]
69. Miao, Hui H and 12 more authors.. (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.. Cancer cell, (7): [PMID:19573808]
70. Jun, Gyungah G and 20 more authors.. (2009) EPHA2 is associated with age-related cortical cataract in mice and humans.. PLoS genetics, [PMID:19649315]
71. Lindauer, Markus M and Hochhaus, Andreas A.. (2010) Dasatinib.. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, [PMID:20072833]
72. Hiramoto-Yamaki, Nao N and 6 more authors.. (2010) Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism.. The Journal of cell biology, (9): [PMID:20679435]
73. Lin, Samantha S, Gordon, Kristin K, Kaplan, Nihal N and Getsios, Spiro S.. (2010) Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.. Molecular biology of the cell, (15): [PMID:20861311]
74. Lupberger, Joachim J and 25 more authors.. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.. Nature medicine, [PMID:21516087]
75. Mercurio, Flavia Anna FA and 5 more authors.. (2012) Solution structure of the first Sam domain of Odin and binding studies with the EphA2 receptor.. Biochemistry, (13): [PMID:22332920]
76. Hahn, Alexander S AS and 15 more authors.. (2012) The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.. Nature medicine, [PMID:22635007]
77. Lee, Hojin H and Bennett, Anton M AM.. (2013) Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration.. Molecular and cellular biology, [PMID:23358419]
78. Tiwari, Amit A and 9 more authors.. (2013) Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors.. PloS one, [PMID:23936024]
79. Zhou, Yue Y and 10 more authors.. (2015) Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.. Nature communications, (9): [PMID:26158630]
80. Barquilla, Antonio A and 5 more authors.. (2016) Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.. Molecular biology of the cell, (1): [PMID:27385333]
81. Zhang, Hua H and 20 more authors.. (2018) Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry.. Nature microbiology, [PMID:29292383]
82. Chen, Jia and 6 more authors.. (2018) Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus.. Nature microbiology, [PMID:29292384]
83. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (1-28). [PMID:29247857]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

MEDI-547 (anti-EphA2)

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器